Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes
Top Cited Papers
Open Access
- 13 January 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 102 (3), 170-178
- https://doi.org/10.1093/jnci/djp482
Abstract
The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence, treatment, and outcomes of ductal carcinoma in situ (DCIS) as a background article for the State of the Science Conference on Diagnosis and Management of DCIS. Published studies were identified and abstracted from MEDLINE and other sources. We include articles published between 1965 and January 31, 2009; 374 publications were identified that addressed DCIS incidence, staging, treatment, and outcomes in adult women. In the United States, DCIS incidence rose from 1.87 per 100 000 in 1973–1975 to 32.5 in 2004. Incidence increased in all ages but more so in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and family history. Although tamoxifen treatment prevented both invasive breast cancer and DCIS, raloxifene treatment decreased incidence of invasive breast cancer but not DCIS. Among patients with DCIS, magnetic resonance imaging was more sensitive than mammography for detecting multicentric disease and estimating tumor size. Because about 15% of patients with DCIS identified on core needle biopsy are diagnosed with invasive breast cancer after excision or mastectomy, the accuracy of sentinel lymph node biopsy after excision is relevant to surgical management of DCIS. Most studies demonstrated that sentinel lymph node biopsy is feasible after breast-conserving surgery (BCS). Younger age, positive surgical margins, tumor size and grade, and comedo necrosis were consistently related to DCIS recurrence. DCIS outcomes after either mastectomy or BCS plus radiation therapy were superior to BCS alone. Tamoxifen treatment after DCIS diagnosis reduced risk of recurrent disease. Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and whether imaging technologies and treatment guidelines can be modified to focus on lesions that are most likely to become clinically problematic.Keywords
This publication has 66 references indexed in Scilit:
- Recent Trends in Breast Cancer Among Younger Women in the United StatesJNCI Journal of the National Cancer Institute, 2008
- Incidence and tumor characteristics of breast cancer diagnosed before and after implementation of a population-based screening-programActa Oncologica, 2008
- Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the BreastAnnals of Surgical Oncology, 2007
- Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With HysterectomyJNCI Journal of the National Cancer Institute, 2007
- Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsyBritish Journal of Surgery, 2007
- MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast CancerNew England Journal of Medicine, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988‐2001Cancer, 2006
- The Influence of Margin Width on Local Control of Ductal Carcinoma in Situ of the BreastNew England Journal of Medicine, 1999
- Recent trends in the incidence of in situ and invasive breast cancer in the Detroit metropolitan area (1975–1988)Cancer, 1993